This report analyzes the worldwide markets for Kidney Cancer Drugs in US$ Million. This report on 'Kidney Cancer Drugs' provides market analytics specifically for the "Renal Cell Carcinoma" (RCC) market, owing to its predominance among the various types of kidney cancers. The market for Renal Cell Carcinoma (RCC) drugs is analyzed by the two major drug classes, which include: Multikinase Inhibitors, and Other RCC drug Classes (including Immunomodulators; mTOR inhibitors; and other emerging drug classes). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 19 companies including many key and niche players such as AVEO Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Co., Onyx Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck-Serono, Novartis AG, Pfizer, Inc., and WILEX AG. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
Global Drug And Medication Industry
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Multikinase Inhibitors I-4
Other RCC drug Classes (including Immunomodulators; mTOR
inhibitors; and other emerging drug classes.) I-4
II. EXECUTIVE SUMMARY
1. KIDNEY CANCER - FACTSHEET II-1
2. MARKET OVERVIEW II-2
Market Scenario II-2
Multikinase Inhibitors Dominate the Market II-2
Presently Approved Drugs for the Treatment of Advanced Renal
Cell Carcinoma (RCC) II-3
Kidney Cancer Bodes Significant Potential for Targeted Therapies II-3
Leading Kidney Cancer Drugs II-4
Pfizer’s Sutent Tops the RCC Drugs Market II-4
Table 1: Leading Kidney Cancer Drugs Worldwide (2009): Sales
for Sutent, Nexavar, Afinitor, Avastin, and Proleukin II-4
GSK’s Votrient Threatens Sutent’s Dominance II-5
Nexavar Dominates Second Line Treatment for RCC II-5
Table 2: Leading Drugs in the Second Line Treatment of RCC
(2011): Market Share Breakdown for Nexavar, Torisel,
Afinitor, Avastin, and Others (includes corresponding
Graph/Chart) II-6
Torisel Leads Third Line Treatment for RCC II-6
Table 3: Leading Drugs in the Third Line Treatment of RCC
(2017E): Market Share Breakdown for Afinitor, Axitinib,
Avastin, Torisel, and Others (includes corresponding
Graph/Chart) II-6
3. KIDNEY CANCER: A GLIMPSE INTO THE DISEASE, CAUSES, SYMPTOMS,
AND DIAGNOSIS II-7
Kidney Cancer: Disease Overview II-7
Causes II-7
Symptoms and Signs II-7
Stages II-7
Renal Cell Carcinoma (RCC): The Most Common Kidney Cancer II-8
Types II-8
Symptoms and Signs II-8
Diagnosis II-8
4. KIDNEY CANCER TREATMENT II-9
Surgical Treatment II-9
Targeted Therapies II-10
Multi-kinase Inhibitors II-10
mTOR Inhibitors II-10
Oral Targeted Therapies II-11
Injectable Targeted Therapy II-11
Pros and Cons of Targeted Therapies II-11
Monoclonal Antibodies II-11
Immunomodulators II-12
Aldesleukin (Proleukin®) II-12
Interferon alpha-2 (Roferon-A®) II-12
5. PROFILES OF MAJOR KIDNEY CANCER DRUGS II-13
Sutent (Sunitinib) II-13
Sutent Vs. Interferon-alpha and IFN-alpha therapies II-13
Nexavar (Sorafenib) II-13
Torisel (Temsirolimus) II-14
Votrient (Pazopanib) II-14
Avastin (Bevacizumab) II-14
Afinitor (Everolimus) II-14
6. PIPELINE ANALYSIS II-15
Select Kidney Cancer Pipeline: As of 2010 II-15
Select Pipeline Drugs - A Review II-15
Axitinib (Pfizer) II-15
Tivozanib (AVEO Pharmaceuticals) II-15
RENCAREX (WILEX) II-16
TroVax (Oxford BioMedica) II-16
7. CANCER STATISTICS II-17
Cancer Incidence - Statistics on New Cases II-17
Table 4: Global Cancer Incidence by Region: 2009 (includes
corresponding Graph/Chart) II-17
Table 5: Global Cancer Incidence by Income Group: 2009
(includes corresponding Graph/Chart) II-17
Table 6: Cancer Incidence in Upper Middle Income Countries by
Site: 2009 (includes corresponding Graph/Chart) II-18
Table 7: Cancer Incidence in Lower Middle Income Countries by
Site: 2009 (includes corresponding Graph/Chart) II-19
Table 8: Cancer Incidence in High Income Countries by Site:
2009 (includes corresponding Graph/Chart) II-20
8. RECENT INDUSTRY ACTIVITY AND PRODUCT APPROVALS II-21
WILEX Grants Exclusive US Commercialisation Rights for
RENCAREX to Prometheus II-21
AVEO Collaborates with Astellas to Develop and Commercialize
Tivozanib II-21
Novartis Sells Proleukin US Rights to Prometheus Laboratories II-21
WILEX Announces End Results of REDECT Phase 3 Registration
Trial with Redectane® II-22
NICE Rejects Novartis’ Kidney Cancer Drug Everolimus II-22
GlaxoSmithKline Gains Conditional EU Approval for Votrient (
pazopanib) II-22
Prometheus and Novartis Enters into Commercialization Agreement II-22
Cipla Launches Soranib Cancer Medicine II-23
Bristol-Myers Squibb Divests Nutrition Business, Mead Johnson
Nutrition, to Focus on Biopharma Business II-23
Roche Acquires Genentech II-23
Novartis’ Afinitor® Obtains EC Approval for Advanced RCC
Treatment II-23
Novartis Obtains FDA Approval for Afinitor II-23
Roche Receives FDA Approval for Avastin in Combination with
Interferon-Alpha for RCC Treatment II-24
Pfizer’s Sutent Obtains Recommendation as First Line Treatment
for mRCC II-24
GlaxoSmithKline Receives FDA Approval for Votrient II-24
9. STRATEGIC CORPORATE DEVELOPMENTS AND PRODUCT APPROVALS - A
HISTORIC PERSPECTIVE BUILDER II-25
Oxford BioMedica’s TroVax Fails Kidney Cancer Clinical Trial II-25
Genomic Health to Collaborate with Pfizer for New Genomic Test II-25
Roche’s Avastin Bags European Approval for Renal Cancer Treatment II-25
Wyeth’s TORISEL Receives FDA Approval II-25
AstraZeneca’s Novel Cancer Drug, AZD2171, Dubbed Recentin II-25
10. FOCUS ON SELECT GLOBAL PLAYERS II-26
AVEO Pharmaceuticals (US) II-26
Bayer AG (Germany) II-26
Bristol-Myers Squibb Co. (US) II-27
Onyx Pharmaceuticals, Inc. (US) II-27
F. Hoffmann-La Roche Ltd. (Switzerland) II-28
GlaxoSmithKline Plc. (UK) II-28
Merck-Serono (Switzerland) II-29
Novartis AG (Switzerland) II-29
Pfizer, Inc. (US) II-29
WILEX AG (Germany) II-30
11. GLOBAL MARKET PERSPECTIVE II-31
Table 9: World Recent Past, Current & Future Analysis for
Renal Cell Carcinoma (RCC) Drugs by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets
Independently Analyzed by Annual Sales Figures in US$ Million
for Years 2008 through 2017 (includes corresponding
Graph/Chart) II-31
Table 10: World 10-Year Perspective for Renal Cell Carcinoma
(RCC) Drugs by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and
Rest of World Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart) II-32
Table 11: World Recent Past, Current & Future Analysis for
Multikinase Inhibitors by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, and Rest of World Markets
Independently Analyzed by Annual Sales Figures in US$ Million
for Years 2008 through 2017 (includes corresponding
Graph/Chart) II-33
Table 12: World 10-Year Perspective for Multikinase Inhibitors
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Markets for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) II-34
Table 13: World Recent Past, Current & Future Analysis for
Other RCC Drugs by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific, and Rest of World Markets Independently
Analyzed by Annual Sales Figures in US$ Million for Years 2008
through 2017 (includes corresponding Graph/Chart) II-35
Table 14: World 10-Year Perspective for Other RCC Drugs by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific, and Rest of World
Markets for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) II-36
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Cancer Statistics in the US III-1
Cancer Incidence Statistics III-1
Table 15: New Cancer Cases in the US by Affected Site: 2009 III-1
Table 16: New Cancer Cases in Males in US by Leading Site:
2009 (includes corresponding Graph/Chart) III-3
Table 17: New Cancer Cases in Females in US by Leading
Site: 2009 (includes corresponding Graph/Chart) III-4
Cancer Mortality Statistics III-4
Table 18: Cancer Related Deaths in the US by Affected Site:
2009 III-4
Table 19: Cancer Related Deaths in Males in US by Leading
Site: 2009 (includes corresponding Graph/Chart) III-6
Table 20: Cancer Related Deaths in Females in US by Leading
Site: 2009 (includes corresponding Graph/Chart) III-7
Kidney Cancer Incidence Rates and Mortality Statistics III-7
Table 21: Kidney Cancer Incidence Rates by Race/Ethnicity
per 10,000 Men (includes corresponding Graph/Chart) III-7
Table 22: Kidney Cancer Incidence Rates by Race/Ethnicity
Per 10,000 Women (includes corresponding Graph/Chart) III-8
Table 23: Kidney Cancer Mortality Rates by Race/Ethnicity
per 10,000 Men (includes corresponding Graph/Chart) III-8
Table 24: Kidney Cancer Mortality Rates by Race/Ethnicity
Per 10,000 Women (includes corresponding Graph/Chart) III-9
NCI Funding for Kidney Cancer on the Rise III-9
Table 25: NCI’s Annual Funding on Kidney Cancer Research
for Years 2007, 2008 & 2009 (includes corresponding Graph
/Chart) III-9
Table 26: Allocation of Funds by Scientific/Research Area
(2009) (includes corresponding Graph/Chart) III-10
Strategic Corporate Developments III-10
Focus on Select Major Players III-13
B.Market Analytics III-15
Table 27: The US Recent Past, Current & Future Analysis for
Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) III-15
Table 28: The US 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) III-16
2. CANADA III-17
A.Market Analysis III-17
Cancer Incidence and Mortality Statistics in Canada III-17
Table 29: New Cancer Cases by Type/Site Among Canadian Men
(2010) (includes corresponding Graph/Chart) III-17
Table 30: New Cancer Cases by Type/Site Among Canadian
Women (2010) (includes corresponding Graph/Chart) III-18
Table 31: Cancer Deaths by Type/Site Among Canadian Men
(2010) (includes corresponding Graph/Chart) III-18
Table 32: Cancer Deaths by Type/Site Among Canadian Women
(2010) (includes corresponding Graph/Chart) III-19
B.Market Analytics III-20
Table 33: Canadian Recent Past, Current & Future Analysis
for Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) III-20
Table 34: Canadian 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) III-21
3. JAPAN III-22
Market Analytics III-22
Table 35: Japanese Recent Past, Current & Future Analysis
for Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) III-22
Table 36: Japanese 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) III-23
4. EUROPE III-24
A.Market Analysis III-24
Cancer Statistics in Europe III-24
Table 37: Cancer Incidence in Europe by Site (2009)
(includes corresponding Graph/Chart) III-24
Strategic Corporate Developments III-25
B.Market Analytics III-26
Table 38: European Recent Past, Current & Future Analysis
for Renal Cell Carcinoma Drugs by Geographic Region -
France, Germany, Italy, UK and Rest of European Markets
Independently Analyzed by Annual Sales Figures in US$
Million for Years 2008 through 2017 (includes corresponding
Graph/Chart) III-26
Table 39: European 10-Year Perspective for Renal Cell
Carcinoma Drugs by Geographic Region - Percentage Breakdown
of Dollar Sales for France, Germany, Italy, UK, and Rest of
European Markets for Years 2008, 2011 & 2017 (includes
corresponding Graph/Chart) III-27
Table 40: European Recent Past, Current & Future Analysis
for Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) III-28
Table 41: European 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) III-29
4a. FRANCE III-30
Market Analytics III-30
Table 42: French Recent Past, Current & Future Analysis for
Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) III-30
Table 43: French 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) III-31
4b. GERMANY III-32
A.Market Analysis III-32
Strategic Corporate Development III-32
Focus on Select Major Players III-32
B.Market Analytics III-34
Table 44: German Recent Past, Current & Future Analysis for
Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) III-34
Table 45: German 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) III-35
4c. ITALY III-36
Market Analytics III-36
Table 46: Italian Recent Past, Current & Future Analysis for
Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) III-36
Table 47: Italian 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) III-37
4d. THE UNITED KINGDOM III-38
A.Market Analysis III-38
Kidney Cancer Statistics III-38
Strategic Corporate Developments III-38
Focus on Select Major Players III-39
B.Market Analytics III-40
Table 48: The UK Recent Past, Current & Future Analysis for
Renal Cell Carcinoma Drugs by Drug Class - Multikinase
Inhibitors and Others Markets Independently Analyzed by
Annual Sales Figures in US$ Million for Years 2008 through
2017 (includes corresponding Graph/Chart) III-40
Table 49: The UK 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) III-41
4e. REST OF EUROPE III-42
A.Market Analysis III-42
Focus on Select Major Players III-42
B.Market Analytics III-43
Table 50: Rest of European Recent Past, Current & Future
Analysis for Renal Cell Carcinoma (RCC) Drugs by Drug Class
- Multikinase Inhibitors and Others Markets Independently
Analyzed by Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) III-43
Table 51: Rest of European 10-Year Perspective for Renal
Cell Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) III-44
5. ASIA-PACIFIC III-45
A.Market Analysis III-45
Cancer Statistics in Asia-Pacific III-45
Table 52: Cancer Incidence in Asia-Oceania by Site: 2009
(includes corresponding Graph/Chart) III-45
Product Launch III-46
B.Market Analytics III-46
Table 53: Asia-Pacific Recent Past, Current & Future
Analysis for Renal Cell Carcinoma (RCC) Drugs by Drug Class
- Multikinase Inhibitors and Others Markets Independently
Analyzed by Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) III-46
Table 54: Asia-Pacific 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) III-47
6. REST OF WORLD III-48
Market Analytics III-48
Table 55: Rest of World Recent Past, Current & Future
Analysis for Renal Cell Carcinoma Drugs by Drug Class -
Multikinase Inhibitors and Others Markets Independently
Analyzed by Annual Sales Figures in US$ Million for Years
2008 through 2017 (includes corresponding Graph/Chart) III-48
Table 56: Rest of World 10-Year Perspective for Renal Cell
Carcinoma Drugs by Drug Class - Percentage Breakdown of
Dollar Sales for Multikinase Inhibitors and Others Markets
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) III-49
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 19 (including Divisions/Subsidiaries - 21)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 10
Canada 1
Europe 9
Germany 3
The United Kingdom 3
Rest of Europe 3
Asia-Pacific (Excluding Japan) 1
------------------------------------------
